AAVGen: Precision Engineering of Adeno-associated Viral Capsids for Renal Selective Targeting
Not on the map. Why?
Abstract (arXiv)
Adeno-associated viruses (AAVs) are promising vectors for gene therapy, but their native serotypes face limitations in tissue tropism, immune evasion, and production efficiency. Engineering capsids to overcome these hurdles is challenging due to the vast sequence space and the difficulty of simultaneously optimizing multiple functional properties. The complexity also adds when it comes to the kidney, which presents unique anatomical barriers and cellular targets that require precise and efficient vector engineering. Here, we present AAVGen, a generative artificial intelligence framework for de novo design of AAV capsids with enhanced multi-trait profiles. AAVGen integrates a protein language model (PLM) with supervised fine-tuning (SFT) and a reinforcement learning technique termed Group Sequence Policy Optimization (GSPO). The model is guided by a composite reward signal derived from three ESM-2-based regression predictors, each trained to predict a key property: production fitness, kidney tropism, and thermostability. Our results demonstrate that AAVGen produces a diverse library of novel VP1 protein sequences. In silico validations revealed that the majority of the generated variants have superior performance across all three employed indices, indicating successful multi-objective optimization. Furthermore, structural analysis via AlphaFold3 confirms that the generated sequences preserve the canonical capsid folding despite sequence diversification. AAVGen establishes a foundation for data-driven viral vector engineering, accelerating the development of next-generation AAV vectors with tailored functional characteristics.
Key facts. Cited by 1 paper in the map (data through 14 Oct 2026). Builds on 3 of its 33 references that are in the map. First posted on arXiv 21 Feb 2026.
Builds on
3 of 33 references.
References · 3
Built on by
Citing papers per year: 2026: 1.
1 paper.
Similar, not cited
Close in wording, no citation either way
- 2026Reinforcement-guided generative protein language models enable de novo design of highly diverse AAV capsids
- 2026DrugGen 2: A disease-aware language model for enhancing drug discovery
- 2026ProDCARL: Reinforcement Learning-Aligned Diffusion Models for De Novo Antimicrobial Peptide Design
- 2024Harnessing Preference Optimisation in Protein LMs for Hit Maturation in Cell Therapy
- 2026Protein-Conditioned Multi-Objective Reinforcement Learning for Full-Length mRNA Design
- 2025A Variational Perspective on Generative Protein Fitness Optimization
- 2025Steering Generative Models with Experimental Data for Protein Fitness Optimization
- 2025ProteinGuide: On-the-fly property guidance for protein sequence generative models